Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

The discovery of immune checkpoint inhibitors (ICIs) has now been universally
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …

Background Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are
distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a
promising approach for cancer treatment in recent years due to the critical roles of the TME …

The immune system is the core defense against cancer development and progression.
Failure of the immune system to recognize and eliminate malignant cells plays an important …

We present an integrated analysis of the clinical measurements, immune cells, and plasma
multi-omics of 139 COVID-19 patients representing all levels of disease severity, from serial …

Despite recent advances in cancer immunotherapy, certain tumor types, such as
Glioblastomas, are highly resistant due to their tumor microenvironment disabling the anti …

Colorectal cancers (CRCs) arise from precursor polyps whose cellular origins, molecular
heterogeneity, and immunogenic potential may reveal diagnostic and therapeutic insights …

Myeloid cells are the most abundant immune components of the tumour microenvironment,
where they have a variety of functions, ranging from immunosuppressive to …